Monday, March 20, 2023 12:26:06 PM
L-2 on $RVVTF was all screwed up this morning and short MMs (convertible MMs even) were all over it, and it was hard to tell what was going on with most OTC stocks this morning. It took over 2 hours for most of the L-2 OTC stock data mess to clear up.
I started buying more RVVTF shares about 30 minutes ago.
There is a huge chart gap overhead formed at the open today, that needs to fill, back up to at least .068 range
No one should have sold the bottom today, that is a rookie mistake.
Bid support seems to be strong at the .037 Fib range now.
The news left a lot of future rally doors open for solid upside. Some body, BP(?) Hedge Funds(?) wanted this stock way down and got it down 70% off the price RVVTF raised 4.3 Million dollars at, namely at .10/share
We can speculate later on what the 2nd half of the PR says that is bullish, lots of bullish options listed.
https://www.proactiveinvestors.com/companies/news/1009552/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-treatment-of-covid-19-1009552.html
Be interesting to see if the CEO bought the dip today and files a form 4.
My opinions on RVVTF have not changed. In fact it is a better buy now than before, who would not buy at 70% off the price they just raised 4.3 Million dollars at? or 95% off the 2 year high?
The FDA trial is still underway.
Google dollar cost averaging folks.
I started buying more RVVTF shares about 30 minutes ago.
There is a huge chart gap overhead formed at the open today, that needs to fill, back up to at least .068 range
No one should have sold the bottom today, that is a rookie mistake.
Bid support seems to be strong at the .037 Fib range now.
The news left a lot of future rally doors open for solid upside. Some body, BP(?) Hedge Funds(?) wanted this stock way down and got it down 70% off the price RVVTF raised 4.3 Million dollars at, namely at .10/share
We can speculate later on what the 2nd half of the PR says that is bullish, lots of bullish options listed.
https://www.proactiveinvestors.com/companies/news/1009552/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-treatment-of-covid-19-1009552.html
Be interesting to see if the CEO bought the dip today and files a form 4.
My opinions on RVVTF have not changed. In fact it is a better buy now than before, who would not buy at 70% off the price they just raised 4.3 Million dollars at? or 95% off the 2 year high?
The FDA trial is still underway.
Google dollar cost averaging folks.
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
